Cancer Clinician Advocacy Forum

What Cancer Clinician Advocacy Forum does

Cancer Clinician Advocacy Forum (CCAF) is a pan-Canadian network of cancer care clinicians — including pharmacists, nurses, and physicians — that advocates for public policy reforms to improve the quality, accessibility, and outcomes of cancer care in Canada. The organization emerged from a two-day Forum held in Toronto in September 2023 and consolidated its early work into a consensus report published in the peer-reviewed journal Current Oncology in February 2024, titled 'Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement.' CCAF is governed by co-chairs (Dr. Sandeep Sehdev and Dr. Nancy A. Nixon) and a steering committee, and operates without commercial products, software platforms, or membership fees; its primary 'outputs' are policy consultation submissions to bodies such as CDA-AMC and the pan-Canadian Pharmaceutical Alliance (pCPA), op-eds and press releases, media appearances, and peer-reviewed publications.

CCAF pursues three stated priority areas: expanding access to diagnostic testing including molecular genetics testing, ensuring faster and more equitable access to new cancer therapies, and improving efficiencies in patient care while addressing human resource constraints. Its go-to-market is community-led advocacy rather than commercial sales: it engages clinicians directly, partners with the CanCertainty Coalition (which represents more than 35 Canadian patient groups, cancer health charities, and caregiver organizations), and uses earned media (CBC, CTV, Global News, Radio-Canada, National NewsWatch) to pressure-test and publicize its policy positions.

CCAF is funded through its partnership with the CanCertainty Coalition via unrestricted financial contributions from nine major pharmaceutical companies operating in Canada — Merck Canada, Eli Lilly Canada, AbbVie Canada, AstraZeneca Canada, Novartis Canada, Roche Canada, Pfizer Canada, BeOne Medicines Canada, and Johnson & Johnson Innovative Medicine Canada — accepted under the Corporate Transparency and Code of Conduct of Kidney Cancer Canada. The organization has no disclosed revenue, budget, headcount detail, or equity ownership structure; it is classified as private, operates as a Canadian clinician advocacy forum, and is active across Canada with bilingual (English/French) outreach.

Name

Cancer Clinician Advocacy Forum

Legal name

Cancer Clinician Advocacy Forum

Website

https://cancerclinicianadvocacy.ca

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Cancer Clinician Advocacy Forum (CCAF) is a pan-Canadian network of cancer care clinicians (physicians, nurses, pharmacists) that advocates for policy reforms to improve access to and quality of cancer care in Canada.

Ownership category

akta.pro rank

GTM type

B2B

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations

Revenue model

1. Coalition Funding and Corporate Contributions: CCAF is funded through a partnership with the CanCertainty Coalition, which receives support from more than 35 partner organizations and corporate donations. Corporate supporters on the CCAF project include unrestricted financial contributions from Merck Canada, Eli Lilly Canada, AbbVie Canada, AstraZeneca Canada, Novartis Canada, Roche Canada, Pfizer Canada, BeOne Medicines Canada, and Johnson & Johnson Innovative Medicine Canada. CCAF and CanCertainty accept corporate support under the Corporate Transparency and Code of Conduct of Kidney Cancer Canada.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels10 records

Core offering

CCAF is a pan-Canadian network of cancer care clinicians (physicians, nurses, pharmacists) that convenes to produce evidence-based position statements and policy recommendations on oncology drug access, cancer care funding, and systemic reform. Its outputs include consensus reports published in peer-reviewed journals and formal submissions to Canadian government bodies, with participation offered free to qualifying clinicians.

Product overview

Cancer Clinician Advocacy Forum (CCAF) is a network of cancer care clinicians across Canada—not a product or technology company. It does not offer commercial products, software, or services. The organization functions as an advocacy coalition of pharmacists, nurses, and physicians committed to improving cancer care policy. CCAF emerged from a two-day Forum in Toronto in September 2023 and published a consensus report in Current Oncology (February 2024) addressing delays in access to cancer technologies and therapies. The organization has no named product portfolio, platform, or modules.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 73% of Ontario oncologists report burnout symptoms, contributing to workforce constraints in cancer care delivery.
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• CanCertainty CoalitioncoreStrategic or Co-development PartnerCCAF is funded through a partnership with the CanCertainty Coalition — the united voice of more than 35 Canadian patient groups, cancer health charities, and caregiver organizations. CanCertainty works with oncologists and cancer care professionals to improve the affordability and accessibility of cancer treatment. CanCertainty's funding is supported by in-kind collaboration from 35+ partner organizations and corporate donations, support from physician and healthcare organizations, and funding from Kidney Cancer Canada. CCAF is a proud partner of the CanCertainty coalition.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Canadian Cancer Society: Canada's largest cancer charity with a policy advocacy function spanning prevention, treatment access, and survivorship. Comparable on the policy-advocacy dimension targeting Canadian regulators, though it is a far broader organization with fundraising, research grants, and support services beyond advocacy.
• European Society for Medical Oncology (ESMO): European clinician oncology society that engages regulators and policymakers on cancer drug access, workforce, and care delivery. Comparable in being a pan-jurisdiction clinician-led oncology advocacy body with formal policy engagement.
• Canadian Medical Association (CMA): National physician advocacy body whose published data on the 18.5 million hours/year of administrative burden CCAF cites in its own materials. Comparable in advocating on clinician workforce, burnout, and system-efficiency issues affecting cancer care delivery.
• American Society of Clinical Oncology (ASCO): Largest U.S. oncology professional society with a substantial policy advocacy arm focused on drug access, reimbursement, and clinician workforce issues. Highly comparable on the clinician-led oncology policy-advocacy dimension, though it operates at much greater scale and primarily in the U.S.
• Canadian Partnership Against Cancer: Federally funded pan-Canadian organization that coordinates cancer system strategy and policy. Operates in the same Canadian oncology policy domain as CCAF, with overlapping concerns around access, equity, and system performance, but with a much broader mandate and government-backed funding model.

Direct peers

• Canadian Breast Cancer Network: National patient-advocacy network for breast cancer; CCAF co-chair Dr. Sehdev serves as a scientific advisor. Highly comparable as a Canadian cancer-access advocacy organization with policy submission and coalition activity.
• Cancer Advocacy Coalition of Canada: Prior Canadian cancer-policy advocacy organization on whose board CCAF co-chair Dr. Sehdev previously served as Director. Directly comparable mission and stakeholder base, though it is no longer clearly active under that name.
• CanCertainty Coalition: Direct partner and funding conduit for CCAF, also a Canadian clinician-and-patient coalition advocating for equitable, affordable cancer treatment access. Highly comparable mission and stakeholder base; differs in leading the patient-group side while CCAF leads the clinician side.
• Kidney Cancer Canada: Canadian disease-specific patient advocacy organization that provides CCAF's governing Corporate Transparency and Code of Conduct framework. Comparable as a cancer-focused Canadian advocacy entity with policy and access-reform objectives, though its lens is disease-specific.
• Canadian Cancer Survivor Network: Canadian patient-advocacy organization on which CCAF co-chair Dr. Sehdev serves as scientific advisor. Comparable advocacy mission focused on cancer patient access and survivorship issues in Canada.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@DavidJStewartMD
• LinkedInlinkedin.com/company/cancer-clinician-advocacy-forum

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cancer Clinician Advocacy Forum